Immunotherapy ALK rearrangement Prognostic Staging Merkel cell carcinoma ADN tumoral circulant Mesenchymal stromal cells Radiofrequency ablation Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy Anti-PD1 Biliopancreatic diversion Beta-catenin Colon cancer Immunohistochemistry Invasive cutaneous squamous cell carcinoma Immunomodulation Colorectal cancer Follow-up Biomarker Antineoplastic agents Biomarkers Body mass index EGFR Bariatric surgery Circulating tumor DNA Anti-CTLA-4 Sonic Hedgehog Treatment Nivolumab Systemic therapy Prognosis Survival Osimertinib Anti-PD1 blockade BRAFV600E mutation Acute generalized exanthematous pustulosis Surgical excision Bisphosphonates Adjuvant Advanced Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation Immune checkpoint inhibitor Anti-PD-1 Radiotherapy Abscopal effect 2-chlorodeoxyadenosine Oncology Anti-PD-1 antibody Non-small cell lung cancer BRAF V600-mutation Lung adenocarcinoma Adjuvant FOLFOX Plasma ACTH BRAFV600E AML Crizotinib Langerhans cell histiocytosis Dabrafenib Chemotherapy Adjuvant therapy Prevention Advanced melanoma Assisted reproductive techniques Metastatic cSCC AZD9291 Targeted therapy Diagnosis Anti-Tumor pharmacology Circulating cell-free DNA Safety Cancer bronchique non à petites cellules Abdominal pain Molecular targeted therapies Antibody-drug conjugate BRAFV600-mutant melanoma BRAF Chemoresistance TNM classification Locally advanced Trametinib Colorectal carcinoma Histiocytosis Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian Metastatic Androgen insensitivity ALK Wnt Children Allelic imbalance Polyomavirus Gastric bypass BRAF V600E Melanoma Cancer Cemiplimab Liver metastases Adverse events Cutaneous squamous cell carcinoma Resistance